Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.82
+0.06 (0.44%)
At close: Jul 3, 2025, 1:00 PM
13.77
-0.05 (-0.36%)
After-hours: Jul 3, 2025, 4:59 PM EDT

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis.

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics logo
Country United States
Founded 2016
IPO Date Jan 31, 2020
Industry Biotechnology
Sector Healthcare
Employees 342
CEO Todd Watanabe

Contact Details

Address:
3027 Townsgate Road, Suite 300
Westlake Village, California 91361
United States
Phone 805 418 5006
Website arcutis.com

Stock Details

Ticker Symbol ARQT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001787306
CUSIP Number 03969K108
ISIN Number US03969K1088
Employer ID 81-2974255
SIC Code 2834

Key Executives

Name Position
Todd Franklin Watanabe M.A. President, Chief Executive Officer and Director
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder and Independent Director
Masaru Matsuda Esq., J.D. Senior Vice President, General Counsel and Corporate Secretary
Dr. Patrick E. Burnett M.D., Ph.D. Executive Vice President and Chief Medical Officer
Larry Todd Edwards Executive Vice President and Chief Commercial Officer
Latha Vairavan Chief Financial Officer
Rajvir Madan Chief Digital and Technology Officer
Amanda Sheldon Head of Corporate Communications
Kent Taylor Senior Vice President of Sales
Aleen Hosdaghian Vice President of Marketing

Latest SEC Filings

Date Type Title
Jul 1, 2025 144 Filing
Jun 18, 2025 144 Filing
Jun 17, 2025 8-K Current Report
May 28, 2025 144 Filing
May 19, 2025 144 Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 8, 2025 SCHEDULE 13G/A Filing
May 8, 2025 144 Filing
May 6, 2025 10-Q Quarterly Report